EDIT
Price
$1.55
Change
+$0.05 (+3.33%)
Updated
May 23 closing price
Capitalization
129.75M
67 days until earnings call
SLDB
Price
$2.81
Change
-$0.08 (-2.77%)
Updated
May 23 closing price
Capitalization
217.82M
Interact to see
Advertisement

EDIT vs SLDB

Header iconEDIT vs SLDB Comparison
Open Charts EDIT vs SLDBBanner chart's image
Editas Medicine
Price$1.55
Change+$0.05 (+3.33%)
Volume$952.67K
Capitalization129.75M
Solid Biosciences
Price$2.81
Change-$0.08 (-2.77%)
Volume$874.59K
Capitalization217.82M
EDIT vs SLDB Comparison Chart
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. SLDB commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and SLDB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (EDIT: $1.55 vs. SLDB: $2.81)
Brand notoriety: EDIT and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 51% vs. SLDB: 56%
Market capitalization -- EDIT: $129.75M vs. SLDB: $217.82M
EDIT [@Biotechnology] is valued at $129.75M. SLDB’s [@Biotechnology] market capitalization is $217.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 1 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • EDIT’s FA Score: 1 green, 4 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 7 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • EDIT’s TA Score: 7 bullish, 3 bearish.
  • SLDB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than SLDB.

Price Growth

EDIT (@Biotechnology) experienced а +2.65% price change this week, while SLDB (@Biotechnology) price change was +1.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

EDIT is expected to report earnings on Jul 30, 2025.

SLDB is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($218M) has a higher market cap than EDIT($130M). EDIT YTD gains are higher at: 22.047 vs. SLDB (-29.750). SLDB has higher annual earnings (EBITDA): -121.9M vs. EDIT (-233.11M). EDIT has more cash in the bank: 270M vs. SLDB (149M). SLDB has less debt than EDIT: SLDB (24.2M) vs EDIT (35M). EDIT has higher revenues than SLDB: EDIT (32.3M) vs SLDB (0).
EDITSLDBEDIT / SLDB
Capitalization130M218M60%
EBITDA-233.11M-121.9M191%
Gain YTD22.047-29.750-74%
P/E RatioN/AN/A-
Revenue32.3M0-
Total Cash270M149M181%
Total Debt35M24.2M145%
FUNDAMENTALS RATINGS
EDIT vs SLDB: Fundamental Ratings
EDIT
SLDB
OUTLOOK RATING
1..100
1610
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
6493
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (19) in the Biotechnology industry is in the same range as EDIT (33). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

SLDB's SMR Rating (95) in the Biotechnology industry is in the same range as EDIT (95). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (64) in the Biotechnology industry is in the same range as SLDB (93). This means that EDIT’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that SLDB’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITSLDB
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 4 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 3 days ago
84%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 11 days ago
90%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OIGYX34.500.01
+0.03%
Invesco Oppenheimer International Gr Y
BMCCX17.35N/A
N/A
BlackRock Advantage Large Cap Gr Inv C
HDSIX20.25N/A
N/A
Hodges Small Cap Institutional
RYMKX48.48N/A
N/A
Rydex Russell 2000 1.5x Strategy H
BBMIX11.18-0.03
-0.27%
BBH Select Series - Mid Cap I